RISEDRONATE TEVA 35 MG

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

şimdi satın al

Aktif bileşen:

RISEDRONIC ACID AS SODIUM

Mevcut itibaren:

ABIC MARKETING LTD, ISRAEL

ATC kodu:

M05BA07

Farmasötik formu:

TABLETS

Kompozisyon:

RISEDRONIC ACID AS SODIUM 35 MG

Uygulama yolu:

PER OS

Reçete türü:

Required

Tarafından üretildi:

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

Terapötik grubu:

RISEDRONIC ACID

Terapötik alanı:

RISEDRONIC ACID

Terapötik endikasyonlar:

Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

Yetkilendirme tarihi:

2011-10-31

Bilgilendirme broşürü

                                RISE TAB PL SH 060218
RISE TAB PL SH 060218
THIS LEAFLET FORMAT HAS BEEN
DETERMINED BY THE MINISTRY OF
HEALTH AND THE CONTENT THEREOF
HAS BEEN CHECKED AND APPROVED
PATIENT PACKAGE INSERT
IN ACCORDANCE WITH THE
PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
The dispensing of this medicine
requires a doctor's prescription.
READ THE PACKAGE INSERT CAREFULLY
IN ITS ENTIRETY BEFORE USING THIS
MEDICINE.
RISEDRONATE TEVA
® 35 MG
TABLETS
COMPOSITION
Each tablet contains:
Risedronate Sodium 35 mg
_Inactive ingredients:_
Lactose monohydrate, pregelatinized
starch, maize starch, colloidal silicon
dioxide, sodium stearyl fumarate,
magnesium stearate, polyvinyl
alcohol, titanium dioxide (E171),
macrogol, talc, iron oxide yellow
(E172), iron oxide red (E172).
Each tablet contains 139.9 mg
lactose.
THERAPEUTIC GROUP
Risedronate belongs to a group of
medicines called bisphosphonates.
THERAPEUTIC ACTIVITY
Risedronate
is
used
to
treat
and
prevent
osteoporosis
in
postmenopausal women and for
treatment of osteoporosis in men at
high risk of fractures.
WHEN SHOULD THE PREPARATION
NOT BE USED?
Do not use Risedronate if you are
pregnant, planning to become
pregnant or breastfeeding.
Do not use Risedronate if you are
sensitive to any of its ingredients.
Do not take this medicine if you
are unable to remain in an upright
position (standing or sitting) for at
least 30 minutes after taking the
medicine.
Do not use this medicine if you
have difficulty swallowing for any
reason.
Do not use this medicine if you are
suffering from hypocalcemia (a low
blood calcium level).
Do not use this medicine in patients
suffering from severe renal failure
(creatinine clearance less than
30 ml/min).
This medicine contains lactose,
therefore should not be used
if you suffer from problems of
galactose intolerance, lactase
deficiency, or glucose and lactose
malabsorption.
DO NOT TAKE THIS MEDICINE WITHOUT
CONSULTING A DOCTOR BEFORE
STARTING TREATMENT
If you are suffering or have suffered in
the past from impaired function of the
kidney, the esophagus, from d
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Bilgilendirme broşürü Bilgilendirme broşürü Arapça 18-03-2018
Bilgilendirme broşürü Bilgilendirme broşürü İbranice 18-03-2018

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin